Antigenic Fingerprinting following Primary RSV Infection in Young Children Identifies Novel Antigenic Sites and Reveals Unlinked Evolution of Human Antibody Repertoires to Fusion and Attachment Glycoproteins

PLoS Pathogens

Volumn 12, Issue 4, 2016, Pages

  Fuentes, Sandra ^a   Coyle, Elizabeth M ^a   Beeler, Judy ^a   Golding, Hana ^a   Khurana, Surender ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HYBRID PROTEIN; PALIVIZUMAB; ATTACHMENT PROTEIN G; GLYCOPROTEIN; PEPTIDE LIBRARY; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS FUSION PROTEIN;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; ANTIGENICITY; ARTICLE; CHILD; ENZYME KINETIC ASSAY; FEMALE; GENE INSERTION; GENOMIC FRAGMENT; HUMAN; IMMUNE RESPONSE; MALE; PHAGE DISPLAY; PROTEIN EXPRESSION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RNA FINGERPRINTING; STRUCTURAL PROTEOMICS; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; INFANT; PEPTIDE LIBRARY;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CHILD; EPITOPES, B-LYMPHOCYTE; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNODOMINANT EPITOPES; INFANT; MALE; PEPTIDE LIBRARY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SURFACE PLASMON RESONANCE; VIRAL ENVELOPE PROTEINS; VIRAL FUSION PROTEINS;

EID: 84964809900     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005554     Document Type: Article

References (57)

1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545–55. doi: 10.1016/S0140-6736(10)60206-120399493; PubMed Central PMCID: PMC2864404.
2. Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G, Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997–2006. Pediatr Infect Dis J. 2012;31(1):5–9. 21817948.
3. Lamprecht CL, Krause HE, Mufson MA, Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis. 1976;134(3):211–7. 977992.
4. Glezen WP, Taber LH, Frank AL, Kasel JA, Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140(6):543–6. 3706232.
5. Lambert L, Sagfors AM, Openshaw PJ, Culley FJ, Immunity to RSV in Early-Life. Front Immunol. 2014;5:466. doi: 10.3389/fimmu.2014.0046625324843; PubMed Central PMCID: PMC4179512.
6. Henderson FW, Collier AM, Clyde WA, Jr.Denny FW, Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med. 1979;300(10):530–4. doi: 10.1056/NEJM197903083001004763253.
7. Johnson KM, Bloom HH, Mufson MA, Chanock RM, Natural reinfection of adults by respiratory syncytial virus. Possible relation to mild upper respiratory disease. N Engl J Med. 1962;267:68–72. doi: 10.1056/NEJM19620712267020414452065.
8. Mufson MA, Orvell C, Rafnar B, Norrby E, Two distinct subtypes of human respiratory syncytial virus. J Gen Virol. 1985;66 (Pt 10):2111–24. doi: 10.1099/0022-1317-66-10-21112413163.
9. Cane PA, Pringle CR, Evolution of subgroup A respiratory syncytial virus: evidence for progressive accumulation of amino acid changes in the attachment protein. J Virol. 1995;69(5):2918–25. 7707517; PubMed Central PMCID: PMC188990.
10. Tan L, Lemey P, Houspie L, Viveen MC, Jansen NJ, van Loon AM, et al. Genetic variability among complete human respiratory syncytial virus subgroup A genomes: bridging molecular evolutionary dynamics and epidemiology. PLoS One. 2012;7(12):e51439. doi: 10.1371/journal.pone.005143923236501; PubMed Central PMCID: PMC3517519.
11. Collins PL, Melero JA, Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus research. 2011;162(1–2):80–99. doi: 10.1016/j.virusres.2011.09.02021963675; PubMed Central PMCID: PMC3221877.
12. Agoti CN, Mwihuri AG, Sande CJ, Onyango CO, Medley GF, Cane PA, et al. Genetic relatedness of infecting and reinfecting respiratory syncytial virus strains identified in a birth cohort from rural Kenya. J Infect Dis. 2012;206(10):1532–41. doi: 10.1093/infdis/jis57022966119; PubMed Central PMCID: PMC3475639.
13. Murphy BR, Prince GA, Walsh EE, Kim HW, Parrott RH, Hemming VG, et al. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol. 1986;24(2):197–202. 3755730; PubMed Central PMCID: PMC268874.
14. Murphy BR, Graham BS, Prince GA, Walsh EE, Chanock RM, Karzon DT, et al. Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J Clin Microbiol. 1986;23(6):1009–14. 3754878; PubMed Central PMCID: PMC268782.
15. Murphy BR, Alling DW, Snyder MH, Walsh EE, Prince GA, Chanock RM, et al. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J Clin Microbiol. 1986;24(5):894–8. 3771779; PubMed Central PMCID: PMC269059.
16. Wagner DK, Graham BS, Wright PF, Walsh EE, Kim HW, Reimer CB, et al. Serum immunoglobulin G antibody subclass responses to respiratory syncytial virus F and G glycoproteins after primary infection. J Clin Microbiol. 1986;24(2):304–6. 3755731; PubMed Central PMCID: PMC268896.
17. Norrby E, Mufson MA, Alexander H, Houghten RA, Lerner RA, Site-directed serology with synthetic peptides representing the large glycoprotein G of respiratory syncytial virus. Proc Natl Acad Sci U S A. 1987;84(18):6572–6. 3476962; PubMed Central PMCID: PMC299121.
18. Cane PA, Analysis of linear epitopes recognised by the primary human antibody response to a variable region of the attachment (G) protein of respiratory syncytial virus. J Med Virol. 1997;51(4):297–304. 9093944.
19. Palomo C, Cane PA, Melero JA, Evaluation of the antibody specificities of human convalescent-phase sera against the attachment (G) protein of human respiratory syncytial virus: influence of strain variation and carbohydrate side chains. J Med Virol. 2000;60(4):468–74. 10686032.
20. Munoz FM, Piedra PA, Glezen WP, Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine. 2003;21(24):3465–7. 12850361.
21. Hall CB, Walsh EE, Long CE, Schnabel KC, Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis. 1991;163(4):693–8. 2010624.
22. Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP, Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine. 2003;21(24):3479–82. 12850364.
23. Walsh EE, Falsey AR, Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis. 2004;190(2):373–8. doi: 10.1086/42152415216475.
24. Falsey AR, Singh HK, Walsh EE, Serum antibody decay in adults following natural respiratory syncytial virus infection. J Med Virol. 2006;78(11):1493–7. doi: 10.1002/jmv.2072416998887.
25. Sastre P, Cusi MG, Manoha C, Schildgen O, Ruiz T, Vela C, et al. Serum antibody response to respiratory syncytial virus F and N proteins in two populations at high risk of infection: children and elderly. J Virol Methods. 2010;168(1–2):170–6. doi: 10.1016/j.jviromet.2010.05.01120488207.
26. Khurana S, Suguitan AL, Jr.Rivera Y, Simmons CP, Lanzavecchia A, Sallusto F, et al. Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med. 2009;6(4):e1000049. Epub 2009/04/22. doi: 10.1371/journal.pmed.100004919381279; PubMed Central PMCID: PMC2661249.
27. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013;342(6158):592–8. doi: 10.1126/science.124328324179220; PubMed Central PMCID: PMC4461862.
28. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997;176(5):1215–24. 9359721.
29. Anderson LJ, Hierholzer JC, Stone YO, Tsou C, Fernie BF, Identification of epitopes on respiratory syncytial virus proteins by competitive binding immunoassay. J Clin Microbiol. 1986;23(3):475–80. 2420819; PubMed Central PMCID: PMC268677.
30. Fuentes S, Coyle EM, Golding H, Khurana S, Nonglycosylated G-Protein Vaccine Protects against Homologous and Heterologous Respiratory Syncytial Virus (RSV) Challenge, while Glycosylated G Enhances RSV Lung Pathology and Cytokine Levels. J Virol. 2015;89(16):8193–205. doi: 10.1128/JVI.00133-1526018164; PubMed Central PMCID: PMC4524247.
31. Kumari S, Crim RL, Kulkarni A, Audet SA, Mdluli T, Murata H, et al. Development of a luciferase immunoprecipitation system assay to detect IgG antibodies against human respiratory syncytial virus nucleoprotein. Clin Vaccine Immunol. 2014;21(3):383–90. doi: 10.1128/CVI.00594-1324403526; PubMed Central PMCID: PMC3957679.
32. Welliver RC, Kaul TN, Putnam TI, Sun M, Riddlesberger K, Ogra PL, The antibody response to primary and secondary infection with respiratory syncytial virus: kinetics of class-specific responses. J Pediatr. 1980;96(5):808–13. 7365579.
33. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013;340(6136):1113–7. doi: 10.1126/science.123491423618766.
34. Kwakkenbos MJ, Diehl SA, Yasuda E, Bakker AQ, van Geelen CM, Lukens MV, et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nature medicine. 2010;16(1):123–8. doi: 10.1038/nm.207120023635; PubMed Central PMCID: PMC2861345.
35. Ngwuta JO, Chen M, Modjarrad K, Joyce MG, Kanekiyo M, Kumar A, et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med. 2015;7(309):309ra162. doi: 10.1126/scitranslmed.aac424126468324; PubMed Central PMCID: PMC4672383.
36. Fuentes S, Crim RL, Beeler J, Teng MN, Golding H, Khurana S, Development of a simple, rapid, sensitive, high-throughput luciferase reporter based microneutralization test for measurement of virus neutralizing antibodies following Respiratory Syncytial Virus vaccination and infection. Vaccine. 2013;31(37):3987–94. doi: 10.1016/j.vaccine.2013.05.08823742994; PubMed Central PMCID: PMC3779065.
37. Anderson LJ, Bingham P, Hierholzer JC, Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. J Virol. 1988;62(11):4232–8. 2459412; PubMed Central PMCID: PMC253856.
38. Corti D, Bianchi S, Vanzetta F, Minola A, Perez L, Agatic G, et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature. 2013;501(7467):439–43. doi: 10.1038/nature1244223955151.
39. Gilman MS, Moin SM, Mas V, Chen M, Patel NK, Kramer K, et al. Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein. PLoS Pathog. 2015;11(7):e1005035. doi: 10.1371/journal.ppat.100503526161532; PubMed Central PMCID: PMC4498696.
40. Krarup A, Truan D, Furmanova-Hollenstein P, Bogaert L, Bouchier P, Bisschop IJ, et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun. 2015;6:8143. doi: 10.1038/ncomms914326333350; PubMed Central PMCID: PMC4569726.
41. Burton CT, Gotch F, Imami N, Rapid qualitative and quantitative analysis of T-cell responses in HIV-1-infected individuals receiving successful HAART and HIV-1 sero-negative controls: concomitant assessment of perforin, IFN-gamma and IL-4 secretion. J Immunol Methods. 2006;308(1–2):216–30. 16388819.
42. Tapia LI, Shaw CA, Aideyan LO, Jewell AM, Dawson BC, Haq TR, et al. Gene sequence variability of the three surface proteins of human respiratory syncytial virus (HRSV) in Texas. PLoS One. 2014;9(3):e90786. doi: 10.1371/journal.pone.009078624625544; PubMed Central PMCID: PMC3953119.
43. Magro M, Mas V, Chappell K, Vazquez M, Cano O, Luque D, et al. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci U S A. 2012;109(8):3089–94. doi: 10.1073/pnas.111594110922323598; PubMed Central PMCID: PMC3286924.
44. Jones PD, Ada GL, Influenza-specific antibody-secreting cells and B cell memory in the murine lung after immunization with wild-type, cold-adapted variant and inactivated influenza viruses. Vaccine. 1987;5(3):244–8. Epub 1987/09/01. 3499714.
45. Jones PD, Ada GL, Persistence of influenza virus-specific antibody-secreting cells and B-cell memory after primary murine influenza virus infection. Cell Immunol. 1987;109(1):53–64. Epub 1987/10/01. 3498544.
46. Hyland L, Sangster M, Sealy R, Coleclough C, Respiratory virus infection of mice provokes a permanent humoral immune response. J Virol. 1994;68(9):6083–6. Epub 1994/09/01. 8057487; PubMed Central PMCID: PMC237018.
47. Purtha WE, Tedder TF, Johnson S, Bhattacharya D, Diamond MS, Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants. J Exp Med. 2011;208(13):2599–606. Epub 2011/12/14. jem.20110740 [pii] doi: 10.1084/jem.2011074022162833; PubMed Central PMCID: PMC3244041.
48. Tarlinton D, Good-Jacobson K, Diversity among memory B cells: origin, consequences, and utility. Science. 2013;341(6151):1205–11. Epub 2013/09/14. 341/6151/1205 [pii] doi: 10.1126/science.124114624031013.
49. Karron RA, Wright PF, Belshe RB, Thumar B, Casey R, Newman F, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis. 2005;191(7):1093–104. doi: 10.1086/42781315747245.
50. Jorquera PA, Choi Y, Oakley KE, Powell TJ, Boyd JG, Palath N, et al. Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease. PLoS One. 2013;8(9):e74905. doi: 10.1371/journal.pone.007490524040360; PubMed Central PMCID: PMC3769300.
51. Zlateva KT, Lemey P, Vandamme AM, Van Ranst M, Molecular evolution and circulation patterns of human respiratory syncytial virus subgroup a: positively selected sites in the attachment g glycoprotein. J Virol. 2004;78(9):4675–83. 15078950; PubMed Central PMCID: PMC387670.
52. Trento A, Abrego L, Rodriguez-Fernandez R, Gonzalez-Sanchez MI, Gonzalez-Martinez F, Delfraro A, et al. Conservation of G-Protein Epitopes in Respiratory Syncytial Virus (Group A) Despite Broad Genetic Diversity: Is Antibody Selection Involved in Virus Evolution?J Virol. 2015;89(15):7776–85. doi: 10.1128/JVI.00467-1525995258; PubMed Central PMCID: PMC4505632.
53. Grad YH, Newman R, Zody M, Yang X, Murphy R, Qu J, et al. Within-host whole-genome deep sequencing and diversity analysis of human respiratory syncytial virus infection reveals dynamics of genomic diversity in the absence and presence of immune pressure. J Virol. 2014;88(13):7286–93. doi: 10.1128/JVI.00038-1424741088; PubMed Central PMCID: PMC4054443.
54. Jaberolansar N, Toth I, Young PR, Skwarczynski M, Recent advances in the development of subunit-based RSV vaccines. Expert Rev Vaccines. 2016;15(1):53–68. doi: 10.1586/14760584.2016.110513426506139.
55. Raghunandan R, Lu H, Zhou B, Xabier MG, Massare MJ, Flyer DC, et al. An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization. Vaccine. 2014;32(48):6485–92. 25269094.
56. Hawthorne JD, Albrecht P, Sensitive plaque neutralization assay for parainfluenza virus types 1, 2, and 3 and respiratory syncytial virus. J Clin Microbiol. 1981;13(4):730–7. 6262372; PubMed Central PMCID: PMC273869.
57. Lu H, Khurana S, Verma N, Manischewitz J, King L, Beigel JH, et al. A rapid Flp-In system for expression of secreted H5N1 influenza hemagglutinin vaccine immunogen in mammalian cells. PLoS One. 2011;6(2):e17297. doi: 10.1371/journal.pone.001729721386997; PubMed Central PMCID: PMC3046144.